News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids Michael O'Riordan November 10, 2025
News Conference News AHA 2025 Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia Caitlin E. Cox November 08, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients Caitlin E. Cox October 16, 2025
News Daily News High Aerobic Fitness Linked to Less Chronic Disease in Later Life Michael O'Riordan October 10, 2025
News Daily News Risk Factors Present in Nearly All Patients Who Develop CVD Michael O'Riordan October 02, 2025
News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Daily News Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions L.A. McKeown September 22, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Daily News Half of Patients Stop Semaglutide for Weight Loss by 1 Year Todd Neale September 18, 2025
News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Daily News AI-Supported Coaching Shows Promise for Improving Glycemic Control L.A. McKeown August 25, 2025
News Daily News Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC Yael L. Maxwell August 18, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025